These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Hypopigmenting activity of bisabolangelone isolated from Angelica koreana Maxim. in α-melanocyte stimulating hormone-activated B16 or melan-a cells. Roh E; Yun CY; Lee JW; Lee C; Hwang BY; Oh ST; Jung SH; Han SB; Kim Y Planta Med; 2011 Feb; 77(3):248-51. PubMed ID: 20814852 [TBL] [Abstract][Full Text] [Related]
23. Torilin from Torilis japonica inhibits melanin production in alpha-melanocyte stimulating hormone-activated B16 melanoma cells. Yun CY; Kim D; Lee WH; Park YM; Lee SH; Na M; Jahng Y; Hwang BY; Lee MK; Han SB; Kim Y Planta Med; 2009 Nov; 75(14):1505-8. PubMed ID: 19533579 [TBL] [Abstract][Full Text] [Related]
24. The mechanism of action and clinical benefits of soy for the treatment of hyperpigmentation. Leyden J; Wallo W Int J Dermatol; 2011 Apr; 50(4):470-7. PubMed ID: 21332714 [TBL] [Abstract][Full Text] [Related]
25. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose. Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020 [TBL] [Abstract][Full Text] [Related]
26. Natural options for the management of hyperpigmentation. Leyden JJ; Shergill B; Micali G; Downie J; Wallo W J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1140-5. PubMed ID: 21623927 [TBL] [Abstract][Full Text] [Related]
27. Clinical and instrumental evaluation of the efficacy of a new depigmenting agent containing a combination of a retinoid, a phenolic agent and an antioxidant for the treatment of solar lentigines. Cameli N; Abril E; Agozzino M; Mariano M Dermatology; 2015; 230(4):360-6. PubMed ID: 25871836 [TBL] [Abstract][Full Text] [Related]
28. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease. Sewerynek J; Wiktorska J; Nowak D; Lewinski A Endocr Regul; 2000 Jun; 34(2):83-9. PubMed ID: 10911409 [TBL] [Abstract][Full Text] [Related]
29. The melanogenesis and mechanisms of skin-lightening agents--existing and new approaches. Gillbro JM; Olsson MJ Int J Cosmet Sci; 2011 Jun; 33(3):210-21. PubMed ID: 21265866 [TBL] [Abstract][Full Text] [Related]
30. Topical agents used in the management of hyperpigmentation. Halder RM; Richards GM Skin Therapy Lett; 2004; 9(6):1-3. PubMed ID: 15334278 [TBL] [Abstract][Full Text] [Related]
31. Natural ingredients for darker skin types: growing options for hyperpigmentation. Alexis AF; Blackcloud P J Drugs Dermatol; 2013 Sep; 12(9 Suppl):s123-7. PubMed ID: 24002160 [TBL] [Abstract][Full Text] [Related]
32. A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids). Mathe N; Balogun M; Yoo J J Cosmet Dermatol; 2021 Jan; 20(1):204-206. PubMed ID: 32997864 [TBL] [Abstract][Full Text] [Related]
33. Kojic Acid for Melasma: Popular Ingredient in Skincare Products. Zachary CM; Wang JV; Saedi N Skinmed; 2020; 18(5):271-273. PubMed ID: 33160435 [TBL] [Abstract][Full Text] [Related]
34. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Callender VD; St Surin-Lord S; Davis EC; Maclin M Am J Clin Dermatol; 2011 Apr; 12(2):87-99. PubMed ID: 21348540 [TBL] [Abstract][Full Text] [Related]
36. Hyperpigmentary disorders: a therapeutic challenge in the dermatological practice. Zielinski Y J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():1. PubMed ID: 23205537 [No Abstract] [Full Text] [Related]
37. Clinical evaluation of the lightening effect of cytidine on hyperpigmented skin. Baswan SM; Leverett J; Pawelek J J Cosmet Dermatol; 2019 Feb; 18(1):278-285. PubMed ID: 30291682 [TBL] [Abstract][Full Text] [Related]
38. Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color. Bhatia A; Hsu JTs; Hantash BM J Drugs Dermatol; 2014 Jan; 13(1):84-5. PubMed ID: 24385124 [No Abstract] [Full Text] [Related]
39. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. Davis EC; Callender VD J Clin Aesthet Dermatol; 2010 Jul; 3(7):20-31. PubMed ID: 20725554 [TBL] [Abstract][Full Text] [Related]
40. Postinflammatory hyperpigmentation secondary to external insult: an overview of the quantitative analysis of pigmentation. Lamel SA; Rahvar M; Maibach HI Cutan Ocul Toxicol; 2013 Mar; 32(1):67-71. PubMed ID: 22667459 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]